Fly News Breaks for March 1, 2016
TEVA, MYL
Mar 1, 2016 | 08:11 EDT
JPMorgan analyst Chris Schott believes delayed generic Epipen competition should drive "significant upside" to Mylan's (MYL) earnings in 2017 and beyond. Teva (TEVA) disclosed last night that it received a complete response letter from the FDA relating to its generic Epipen application. The analyst keeps Overweight ratings on both names.
News For MYL;TEVA From the Last 2 Days
There are no results for your query MYL;TEVA